89bio, Inc. (ETNB)
Oct 30, 2025 - ETNB was delisted (reason: acquired by RHHBY)
14.84
0.00 (0.00%)
Inactive · Last trade price on Oct 29, 2025
Company Description
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.
Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia.
89bio, Inc. was formerly known as 89Bio Ltd. and changed its name to September 2019. The company was founded in 2018 and is based in San Francisco, California.
As of October 29, 2025, 89bio, Inc. operates as a subsidiary of Roche Holding AG.
89bio, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Nov 11, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 93 |
| CEO | Rohan Palekar |
Contact Details
Address: 655 Montgomery Street, Suite 1500 San Francisco, California 94111 United States | |
| Phone | 415 432 9270 |
| Website | 89bio.com |
Stock Details
| Ticker Symbol | ETNB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001785173 |
| CUSIP Number | 282559103 |
| ISIN Number | US2825591033 |
| Employer ID | 83-1114349 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rohan Palekar | Chief Executive Officer and Director |
| Ryan Stephen Martins | Chief Financial Officer |
| Francis W. Sarena J.D. | Chief Operating Officer |
| Quoc Le-Nguyen | Chief Technical Officer |
| Dr. Harry Mansbach M.D. | Chief Medical Officer |
| Shiva K. Natarajan CPA | Senior Vice President of Finance and Principal Accounting Officer |
| Annie J. Chang M.B.A. | Vice President of Investor Relations and Corporate Communications |
| Amanda Kurihara | Vice President of People and Culture |
| Melissa Abel | Senior Vice President of Commercial Strategy |
| Michael Baldwin | Senior Vice President and Head of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2025 | POSASR | Filing |
| Oct 30, 2025 | POSASR | Filing |
| Oct 30, 2025 | POS AM | Post-Effective amendments for registration statement |
| Oct 30, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 30, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 30, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 30, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 30, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 30, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 30, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |